Shape-HF Cardiopulmonary Testing System Assesses Heart-Lung Interaction
The Shape-HF Cardiopulmonary Testing System, developed by Shape Medical Systems Inc., is a noninvasive medical device to assess heart-lung interaction and ventilation in patients with chronic heart failure and other cardiopulmonary disease.
While gas exchange testing devices have been used for several years to measure cardiopulmonary response to exercise, Shape-HF is reportedly the first device specifically designed for cardiology. The maker said the Shape-HF is FDA-approved, easy to use, easy on the patient, and provides clinically relevant data that is easy to understand, reproducible and immediately useful to a cardiologist.
Shape-HF uses low-intensity, sub-maximal or steady state testing protocols to allow testing of even high-risk patients with little or no discomfort.
The company said measuring patient gas exchange is the best method of assessing patient functional capacity, monitoring their response to therapy and predicting outcome. Shape-HF is designed to quantify the severity of dyspnea on exertion and fatigue and evaluate the interaction between the heart, lungs, and other organ systems. This makes it possible for the physician to evaluate therapy options for the individual patient and track patient progress. In addition, cardiac resynchronization therapy (CRT) has become a mainstay in treating patients with severe heart failure when alternative treatment options have been exhausted.
The company says this is the first device that objectively measures cardiopulmonary gas exchange easily and quickly without undue strain on the patient and in the office setting. Shape-HF provides real-time physiological assessment to enable CRT optimization during exercise and is cost-effective and easy to use.